ASX
Paradigm Biopharmaceuticals Limited
PAR:ASX•Healthcare
Sensitive ASX Announcement
PARADIGM RECEIVES KEY REGULATORY APPROVALS FOR MPS VI STUDY
Published: 18/06/21, 09:09am (AEST)•3 pages